IMEMR
EMRO
66.92
Index Copernicus
ICICICICICICICIC
Volume 6, Issue 2 (2025)
J Clinic Care Skill 2025, 6(2): 1001-1013 |
Back to browse issues page
Article Type:
Subject:
Ethics code: IR.YUMS.REC.1400.119
History
Received: 2025/06/5 | Accepted: 2025/07/8 | Published: 2025/04/30
Received: 2025/06/5 | Accepted: 2025/07/8 | Published: 2025/04/30
How to cite this article
Fazeli M A, Malekzadeh M, Bayatmanesh H, Neysarian P, Arefkhaha N, Sedaghattalab M. A Comparison of the Effects of Interferon Beta-1 (IFN-beta-1) and Dexamethasone on the Treatment of Hospitalized COVID-19 Patients. J Clinic Care Skill 2025; 6 (2) :1001-1013
URL: http://jccs.yums.ac.ir/article-1-403-en.html
URL: http://jccs.yums.ac.ir/article-1-403-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Authors
Mohammad amin Fazeli, Mohammad Malekzadeh, Habibeh Bayatmanesh, Parisa Neysarian, Nasir Arefkhaha, Moslem Sedaghattalab *1
1- , moslem.sedaghattalab@gmail.com
Abstract (227 Views)
Background: Despite the emergency need for treat the COVID-19 pandemic, there is no effective treatment to date. The present study aimed to compare the effects of interferon Beta-1 and dexamethasone on the treatment of hospitalized COVID-19 patients.
Methods: This phase 2, open-label, and randomized trial examined adult patients who admitted to hospitals of Yasuj, Iran from October 2021 to May 2022 due to COVID-19. Patients were randomly assigned into the intervention group1(88 patient), including Remdesivir, Interferon beta-1, and dexamethasone, and the intervention group2 (88 patient), including Remdesivir and dexamethasone in a ratio of 1:1. The mean arterial blood oxygen(O2) saturation, and length of hospitalization of both groups were compared.
Results: The two groups had no significant difference in terms of demographic characteristics, and disease related variables at the beginning of the study (P>0.05).
The mean and standard deviation of the O2 saturation at the time of discharge in group1 (90.14 ± 10.72) and group2 (92.54 ± 3.19) showed a significant difference (p<0.05). The mean and standard deviation of the length of hospitalization in the group1 (7.02 ± 2.56) and group2 (5.73 ± 2.04) were significantly different (p<0.01). There was a significant difference between the number of deaths in group 1 (7 people) and group 2 (0 people). (P<0.01).
Conclusions: The administration of remdesivir and dexamethasone compared to remdesivir, dexamethasone, and interferon decreased the length of hospitalization, mortality and improved O2 saturation.
Methods: This phase 2, open-label, and randomized trial examined adult patients who admitted to hospitals of Yasuj, Iran from October 2021 to May 2022 due to COVID-19. Patients were randomly assigned into the intervention group1(88 patient), including Remdesivir, Interferon beta-1, and dexamethasone, and the intervention group2 (88 patient), including Remdesivir and dexamethasone in a ratio of 1:1. The mean arterial blood oxygen(O2) saturation, and length of hospitalization of both groups were compared.
Results: The two groups had no significant difference in terms of demographic characteristics, and disease related variables at the beginning of the study (P>0.05).
The mean and standard deviation of the O2 saturation at the time of discharge in group1 (90.14 ± 10.72) and group2 (92.54 ± 3.19) showed a significant difference (p<0.05). The mean and standard deviation of the length of hospitalization in the group1 (7.02 ± 2.56) and group2 (5.73 ± 2.04) were significantly different (p<0.01). There was a significant difference between the number of deaths in group 1 (7 people) and group 2 (0 people). (P<0.01).
Conclusions: The administration of remdesivir and dexamethasone compared to remdesivir, dexamethasone, and interferon decreased the length of hospitalization, mortality and improved O2 saturation.
Keywords: